In this week’s installment of InnovationRx, we explore developments in biotechnology mergers and acquisitions, the ascent of India’s Anthem Biosciences, and other key industry news.
Biotech M&A Activity Accelerates
Healthcare mergers and acquisitions are experiencing a significant upswing. The pharmaceutical sector recorded $65 billion in deals during the first quarter of 2026, marking the highest volume since 2020. According to new data from accounting firm PwC, sixteen of these transactions were valued at $1 billion or more.
A primary driver behind this increased deal-making is the impending expiration of patents for blockbuster drugs, including Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. These expirations are projected to impact pharmaceutical companies’ revenues. The strategic imperative to offset these anticipated revenue declines helps explain the focus of many acquisitions this year, such as Gilead’s $8.2 billion purchase of cancer biotech Arcelix, Lilly’s $7.8 billion acquisition of neurology-focused Cantesa Pharmaceuticals, and Merck’s $6.7 billion deal for oncology startup Terns Pharmaceuticals. These acquisitions center on next-generation therapeutic modalities expected to benefit from extended patent protection.
Despite some political opposition, major pharmaceutical firms continue to pursue licensing agreements for therapies originating from China. Chinese biotechs have transitioned from being fast followers to becoming significant innovators in the field. The PwC report highlights that these companies are sought after for “truly innovative molecules across oncology, immunology, and metabolic disease.” Furthermore, the report’s authors note that large acquirers can often secure more favorable deal terms with Chinese startups compared to their American and European counterparts.
The trend of M&A activity is expected to persist over the next six months. Not only do large pharmaceutical companies have a strong rationale for acquiring assets, but biotechs may increasingly consider selling their ventures. This is due to the persistently challenging environment for initial public offerings (IPOs), which largely remains accessible only to startups with products that are either already approved or nearing the conclusion of their clinical development phases.
Inside The Rise Of India’s Anthem Biosciences
After a twenty-year tenure at the Indian biopharmaceutical company Biocon, where he ascended to a senior management position overseeing marketing, Ajay Bhardwaj made a pivotal career change. His former supervisor was Kiran Mazumdar-Shaw, the visionary founder and chairman of Biocon, who is recognized as a pioneer in Indian biotechnology and the nation’s first self-made female billionaire.
Bhardwaj departed Biocon after being overlooked for a promotion. At 46 years old, with two children needing support for their university education, he invested his entire savings into establishing Anthem Biosciences in 2006. Anthem Biosciences provides outsourcing services to pharmaceutical companies, covering all phases of drug development. Bhardwaj described the venture as “a huge gamble” in a March interview conducted at the company’s headquarters, located in an industrial zone on the outskirts of Bangalore.
The timing of his venture proved fortuitous. Pharmaceutical companies, grappling with escalating costs and diminishing success rates in bringing new drugs to market, increasingly turned to outsourcing as a strategy to enhance efficiency and reduce expenses. A 2024 report commissioned by Anthem from the research firm Frost & Sullivan indicates that only one in 10,000 to 15,000 compounds entering preclinical trials ultimately achieve FDA approval. Moreover, the duration required for new drug development has more than doubled since the 1970s, now exceeding 13 years. For American pharmaceutical firms, outsourcing to Indian companies can yield savings of up to 75% on R&D expenditures and 55% on manufacturing costs.
Bhardwaj’s initial investment, equivalent to $9 million at historical exchange rates, funded through the sale of his 1% stake in Biocon and a bank loan, has yielded substantial returns. Anthem has emerged as one of India’s most highly valued companies in the sector, with a recent market capitalization of $4.5 billion. Its successful IPO in July 2025 marked the first appearance of the 65-year-old founder on Forbes’ Billionaires list, with a net worth of $2.4 billion.
Bhardwaj is now focused on expansion initiatives, including allocating capital for the construction of a new factory near Bangalore. This expansion aims to nearly quintuple sales to $1 billion, a target analysts predict he could achieve within approximately seven years.
What We’re Reading
Companies are enhancing their In Vitro Fertilization (IVF) benefits, a trend likely to continue given national discussions surrounding birth rates.
The White House has expressed a desire to increase the number of physicians, yet its immigration policies present obstacles to achieving this goal.
A debate is ongoing among fertility specialists and bioethicists regarding a novel approach to precisely editing human embryo genes, with discussions centered on its potential for medical cures versus the creation of “designer babies.”
New federal reports indicate that major Medicare insurers frequently deny requests for nursing home stays.
Otsuka acquired the psychiatric treatment biotech Transcend Therapeutics for $700 million.
Business Style Takeaway: The pharmaceutical industry is undergoing a significant consolidation phase driven by patent cliffs and the pursuit of novel therapies, creating substantial opportunities for both acquirers and innovative biotechs. Simultaneously, India’s growing prominence in drug development outsourcing, exemplified by Anthem Biosciences, underscores the global shift towards cost-effective and efficient R&D solutions.
According to the portal: www.forbes.com